Table 1.

Clinical trials of NSCLC vaccines encoding TAAs.

Name	Formulation	TAA	Phase	Number of Patients Enrolled	Disease Stage	Endpoints	Results	NCT Identification	Reference
Cell-based
GVAX	Cell-based	Autologous tumor cells mixed with an allogeneic GM-CSF-secreting cell line	I/II	86	IV	Safety and vaccine manufacturing feasibility	Positive	NCT00074295	Nemunaitis et al., 2006 [31]
Belagenpumatucel-L	Cell-based	4 TGF-β2-antisense gene-modified, irradiated, allogeneic NSCLC cell lines	III	532	IIIA-B/IV	OS	Negative	NCT00676507	Giaccone et al., 2015 [32]
1650-G	Cell-based	Allogeneic NSCLC cell line 1650 + GM-CSF	II	12	I-IIB (adjuvant)	Measurable immunologic response to vaccine	Positive	NCT00654030	Hirschowitz et al., 2011 [33]
Peptide-based
MAGE-A3	Peptide-based	MAGE-A3	III	2312	IB-IIA (adjuvant)	PFS	Negative	NCT00480025	Vansteenkiste et al., 2016 [24]
CIMAvax-EGF	Peptide-based	Epidermal Growth Factor	III	579	IIIB-IV	OS	Negative	-	Rodriguez et al., 2016 [34]
Racotumomab-alum	Peptide-based	NeuGcGM3	III	1082	IIIA-IV	OS	Positive	NCT01460472	Alfonso et al., 2014 [35]
Tecemotide (L-BLP25)	Peptide-based	MUC1	III	1513	III	OS	Negative	NCT00409188	Butts et al., 2014 [36]
PRAME	Peptide-based	PRAME	I	60	IB, II, IIIA	Dose limiting toxicity and humoral immune response	Negative	NCT01159964	Pujol et al., 2016 [37]
Virus-based
TG4010	Virus-based	MUC1	II	65	III/IV	Tumor Response	Negative	NCT00415818	Ramlau et al., 2008 [38]
LV305	Virus-based	NY-ESO-1	I	47	III/IV	Safety and tolerability	Positive	NCT02122861	Somaiah et al., 2019 [39]